Combinatorial Nutraceutical Supplement Pill (CNSP) activates naïve adult telomerase positive stem cells in-situ to heal cardiomyopathies
1 Chief Science Officer, Dragonfly Foundation for Research and Development, Macon, GA 31210 USA.
2 Henry E Young PhD Regeneration Technologies, Macon, GA 31210 USA.
Research Article
GSC Advanced Research and Reviews, 2023, 16(02), 099–111.
Article DOI: 10.30574/gscarr.2023.16.2.0330
Publication history:
Received on 23 June 2023; revised on 02 August 2023; accepted on 05 August 2023
Abstract:
Thirty percent of all deaths worldwide can be attributed to cardiovascular diseases. Myocardial infarction is due to one or more blocked coronary vessels. Following a myocardial infarction, the damaged myocardium is often replaced with non-functional scar tissue, resulting in heart failure. The prognosis of patients with heart failure is poor, with failure rates approaching 50%. Lack of blood flow is a major contributor. Multiple strategies have been developed to restore blood flow to the damaged myocardium. These strategies include pharmacological treatments, reopening the blockage with stents, bypassing the blockage with coronary arterial bypass grafts, and/or forming new blood vessels with stem cells. Since none of these strategies have proved to be permanent fixes, ex vivo activated adult telomerase-positive stem cells (aTPSCs) were examined to restore the damaged myocardium and vasculature of the heart. Individuals with cardiac outputs >25% were treated with ex vivo activated aTPSCs. Following treatment, cardiac output increased from 20-45% for 12+ years in these individuals. These results suggest that ex vivo activated aTPSCs are a viable option for the treatment of individuals with cardiovascular disease. Unfortunately, some individuals with cardiac outputs at or below 10% are too fragile to undergo the ex vivo activated aTPSC procedures. Therefore, a nutraceutical formulation (CNSP) was developed to activate the aTPSCs in-situ for cardiac repair. In an individual with a cardiac output of less than 10%, cardiac output increased by 25% following six months ingestion of CNSP. And increased cardiac output of 10-15% occurred after an additional 12-36+ months of CNSP.
Keywords:
Cardiomyopathy; CNSP; aTPSCs; Stem cells; Myocardial infarction; Regenerative medicine
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
